Specifically, GWAS meta-analysis in schizophrenia by the
Psychiatric Genomics Consortium (PGC) schizophrenia group
has identified 128 independent associations spanning that meet
genome-wide significance in 108 genomic regions notably
including the dopamine D2 receptor locus, but also many other
neurotransmitter genes, especially those involved in central nervous
system (CNS) calcium and glutamate signalling. Thank you for your
question
RasGRP1 may mediate risk for SCZ by involving DLPFC and
peripheral blood, thus encouraging further studies to explore its
possible role as a biomarker of the disease and/or a target for new
medication.
A bioinformatical approach used to find indications for drug
repositioning to produce new treatment paradigms for
schizophrenia by comparing the binding profiles of currently
available clinical compounds to targets or sets of targets derived
from genome-wide association studies (GWAS) or other genetic
studies. Thank you for your question!
